Arcutis Biotherapeutics(US:ARQT) Investors·2025-09-29 15:33Group 1 - Arcutis Biotherapeutics (ARQT) is currently breaking out past two buy points, making it a top stock to watch in the S&P 500 for 2025 [1] - The company specializes in developing dermatology treatments for immune-related skin diseases and conditions, with its main product Zoryve foam approved by the U.S. FDA [1] - The Dow Jones index was flat as President Trump prepared for shutdown talks, while stocks like EA, Nvidia, and Tesla experienced rallies [2] Group 2 - Palantir is facing competition from Lockheed Martin as it aims for significant growth in the S&P 500, being noted as the index's biggest winner in 2025 [4] - The market is currently influenced by AI and gold, which are yielding substantial winners, with several stocks joining the IBD 50 list [4] - Despite a recent decline in indexes, stocks like Nvidia and Palantir are nearing buy points, with upcoming Fed inflation data expected to impact market movements [4]